Wayne State
University researchers have synthesized a series of novel aminoglycoside
antibiotics that have shown enhanced antibacterial activity, low susceptibility
to existing resistance mechanisms and low toxicity when compared to currently
marketed aminoglycosides. Aminoglycoside antibiotics have been used against a
wide variety of bacterial infections caused by Gram-positive and Gram-negative
bacteria. The activity of the aminoglycosides is due to binding to bacterial
RNA. Currently marketed aminoglycoside antibiotics are indicated for treatment
of serious bacterial infections, but are limited in use due to concerns of
serious adverse reactions in the inner ear and kidney. The WSU compounds have
shown impressive effectiveness and low likelihood of toxicity in research to
date.
Commercial
Applications
·
Development
of antibiotics useful in the treatment of bacterial
infections
Technological
Advantage
·
These
antibiotics are designed on the structure of a related compound bound to the
target RNA site and show excellent biological
activity.
Patent
Status
U.S. Patent
10/415,732
Tech
ID
00-525
